CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Off-Label Use of Intravenous Immunoglobulin for Non-Neurological Paraneoplastic Disorders: A Review of Clinical Effectiveness

Last updated: April 30, 2018
Project Number: RC0988-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical effectiveness of the off-label use of intravenous and subcutaneous immunoglobulin for the treatment of non-neurological paraneoplastic disorders?

Key Message

No studies that met pre-specified eligibility criteria were identified